Vor Biopharma’s Recent Performance and Contextual Overview

Market Activity

During the 24‑hour period concluding at 10:44 AM Central Europe on Thursday, 22 October 2026, Vor Biopharma (ticker: VOR) experienced a modest decline of ‑0.47 %. At the time of reporting, one share was priced at approximately USD 18.94 on major exchanges. The company’s outstanding share base stands at 59.4 million, translating to a market capitalization near USD 1.1 billion. In the same 24‑hour window, the trading volume totaled around USD 15.5 million.

When viewed over a longer horizon, VOR’s shares have fallen ‑13.91 % since the end of the previous month, underscoring a downward trend that investors must monitor. The simple moving average over the last 200 days is USD 17.12, indicating that the current price sits roughly US$1.8 above the long‑term average. The most recent 52‑week high—USD 28.66 recorded on 28 October 2025—remains a notable distance away from today’s level, while the 52‑week low of USD 6.50 (20 November 2025) demonstrates the stock’s volatility.

In the same 24‑hour window, several peer companies in the biopharmaceutical sector displayed varied movements:

  • Cvr (UAN) traded +0.14 %, now at USD 127.08, with a market cap of USD 1.3 billion and a price‑to‑earnings ratio of 8.39.
  • Uniti (UNIT) declined ‑2.90 %, now at USD 5.35, sharing a market cap of USD 1.3 billion and a price/earnings ratio of 1.7.
  • Nektar Therapeutics (NKTR) fell ‑2.42 %, trading at USD 38.27, with a market cap of USD 1.3 billion.
  • Taysha Gene Therapies (TSHA) gained +0.24 %, currently at USD 4.12, also with a market cap of USD 1.3 billion.

These figures illustrate a sector that is broadly mixed, with a few outliers moving higher while others exhibit sharper declines. Investors should consider the broader context of each company’s pipeline, regulatory status, and market positioning when assessing relative performance.

Company Overview

Vor BioPharma Inc. operates as a clinical‑stage cell‑therapy developer within the health‑care sector, focusing on the creation of novel therapies for cancer treatment. The company’s core research emphasizes technologies capable of selectively targeting malignant cells while sparing healthy tissue—a strategy that could reduce side effects and improve therapeutic outcomes. Vor Biopharma’s primary markets are the United States, and its corporate information is available through its official website, www.vorbio.com . The stock is listed on the Nasdaq exchange.

The information presented herein reflects market conditions and corporate data as of the stated dates. For the latest updates, investors should consult official filings and reputable financial data providers.